Eli Lilly and Company
LLY#38 of 134 by buybacksNYSE · Healthcare · Drug Manufacturers - General · USA
lilly.comBuybacks · TTM to Jun 2026$6.17Blatest four quarters
Buyback yield0.6%repurchases ÷ market cap
Dividends · TTM to Jun 2026$5.78Bdividend yield 0.6%
Shareholder yield1.1%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−6.3%894M shares (2026)
Buybacks ÷ free cash flow31%payout incl. dividends 60%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $4.11B | $5.38B | $8.97B |
| FY2024Dec 2024 | $2.50B | $4.68B | $3.76B |
| FY2023Dec 2023 | $750M | $4.07B | −$3.15B |
| FY2022Dec 2022 | $1.50B | $3.54B | $4.60B |
| FY2021Dec 2021 | $1.25B | $3.09B | $5.39B |
| FY2020Dec 2020 | $500M | $2.69B | $4.47B |
| FY2019Dec 2019 | $4.40B | $2.41B | $3.48B |
Repurchases in FY2025 were +64.3% versus the prior year.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbo…
- Market cap
- $1.05T
- P/E (trailing)
- 39.3×
- Fiscal year end
- December
- ISIN
- US5324571083
- Reporting currency
- USD
- Data updated
- Oct 10, 2026